104 related articles for article (PubMed ID: 17673375)
21. Chfr inactivation is not associated to chromosomal instability in colon cancers.
Bertholon J; Wang Q; Falette N; Verny C; Auclair J; Chassot C; Navarro C; Saurin JC; Puisieux A
Oncogene; 2003 Dec; 22(55):8956-60. PubMed ID: 14654793
[TBL] [Abstract][Full Text] [Related]
22. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas.
Chen T; Triplett J; Dehner B; Hurst B; Colligan B; Pemberton J; Graff JR; Carter JH
Cancer Res; 2001 Jun; 61(12):4679-82. PubMed ID: 11406536
[TBL] [Abstract][Full Text] [Related]
24. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
25. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
[TBL] [Abstract][Full Text] [Related]
26. CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
Gao L; Liu F; Zhang H; Sun J; Ma Y
Genes Chromosomes Cancer; 2016 Feb; 55(2):158-68. PubMed ID: 26542416
[TBL] [Abstract][Full Text] [Related]
27. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
28. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
29. beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues.
Gréen H; Rosenberg P; Söderkvist P; Horvath G; Peterson C
Cancer Lett; 2006 May; 236(1):148-54. PubMed ID: 16002208
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia.
Wagner M; Schmelz K; Dörken B; Tamm I
Leuk Res; 2008 Jul; 32(7):1054-60. PubMed ID: 18206228
[TBL] [Abstract][Full Text] [Related]
31. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
[TBL] [Abstract][Full Text] [Related]
32. CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB.
Kashima L; Toyota M; Mita H; Suzuki H; Idogawa M; Ogi K; Sasaki Y; Tokino T
Oncogene; 2009 Jul; 28(29):2643-53. PubMed ID: 19448676
[TBL] [Abstract][Full Text] [Related]
33. Epigenetics and ovarian cancer.
Nephew KP; Balch C; Zhang S; Huang TH
Cancer Treat Res; 2009; 149():131-46. PubMed ID: 19763434
[No Abstract] [Full Text] [Related]
34. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
35. p53 in drug resistance in ovarian cancer.
Lavarino C; Delia D; Di Palma S; Zunino F; Pilotti S
Lancet; 1997 May; 349(9064):1556. PubMed ID: 9167490
[No Abstract] [Full Text] [Related]
36. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
37. [Methylation of promoter region of RAR-beta2 gene in renal cell, breast, and ovarian carcinomas].
Khodyrev DS; Loginov VI; Pronina IV; Kazubskaia TP; Gar'kavtseva RF; Braga EA
Genetika; 2008 Aug; 44(8):1126-32. PubMed ID: 18825962
[TBL] [Abstract][Full Text] [Related]
38. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.
Lim SO; Gu JM; Kim MS; Kim HS; Park YN; Park CK; Cho JW; Park YM; Jung G
Gastroenterology; 2008 Dec; 135(6):2128-40, 2140.e1-8. PubMed ID: 18801366
[TBL] [Abstract][Full Text] [Related]
40. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
